NR4A1 and breast carcinoma: Finally, MONARCH + was a phase III, randomised, double-blind clinical trial which included 463 postmenopausal women from China, Brazil, India, and South Africa who had advanced breast cancer, positive hormone receptors, and HER-2 negative [31].